相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Advances in Supportive Care for Multiple Myeloma
Noopur S. Raje et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
H. Eda et al.
LEUKEMIA (2014)
Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases
E. Michael Lewiecki
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2014)
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma
Samantha Pozzi et al.
BONE (2013)
Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis
Martyn K. Robinson et al.
DRUG DISCOVERY TODAY (2013)
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
M. A. Hurchla et al.
LEUKEMIA (2013)
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
T. Scullen et al.
LEUKEMIA (2013)
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
A. J. Jakubowiak et al.
LEUKEMIA (2013)
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
A. Z. Badros et al.
LEUKEMIA (2013)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
Sundar Jagannath et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy
Evangelos Terpos et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation
N. Giuliani et al.
LEUKEMIA (2012)
Sclerostin is overexpressed by plasma cells from multiple myeloma patients
Giacomina Brunetti et al.
SKELETAL BIOLOGY AND MEDICINE I (2011)
Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
Noopur Raje et al.
CLINICAL CANCER RESEARCH (2011)
New targets for intervention in the treatment of postmenopausal osteoporosis
E. Michael Lewiecki
NATURE REVIEWS RHEUMATOLOGY (2011)
Myeloma cells suppress osteoblasts through sclerostin secretion
S. Colucci et al.
BLOOD CANCER JOURNAL (2011)
Bone Anabolic Agents for the Treatment of Multiple Myeloma
Sonia Vallet et al.
CANCER MICROENVIRONMENT (2011)
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression
Gisela Ruiz Heiland et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Guidelines for Assessment of Bone Microstructure in Rodents Using Micro-Computed Tomography
Mary L. Bouxsein et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Mariateresa Fulciniti et al.
BLOOD (2009)
Wnt signaling as a therapeutic target for bone diseases
Luke H. Hoeppner et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
N. Raje et al.
LEUKEMIA (2009)
The pathogenesis of the bone disease of multiple myeloma
Claire M. Edwards et al.
BONE (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Fred Saad et al.
CANCER (2007)
Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
Nicola Giuliani et al.
BLOOD (2006)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling
XF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist
RL van Bezooijen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Investigation of multipotent postnatal stem cells from human periodontal ligament
BM Seo et al.
LANCET (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp
S Shi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation
K Nakashima et al.
CELL (2002)
分享论文
